The 2020 forecasted earnings estimate for BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 76.50) for the year ending December 31, 2020 has been...
The 2020 forecasted earnings estimate for BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 73.59) for the year ending December 31, 2020 has been...
The December 31, 2020 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 76.69) has been increased. The current...
BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 76.02) consensus estimates for Q3 ending September 30, 2019, and the full year forecasts for 2019 and...
| Address | 770 Lindaro Street San Rafael, California 94901 |
| Phone | +1.415.506.6700 |
| Number of Employees | 2,849 |
| Recent SEC Filing | 08/08/2019 4 |
| Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
| Chief Financial Officer & Executive Vice President | Dan Spiegelman |
| Chief Information Officer | Eduardo E. Von Pervieux |
| Chief Medical Officer & Senior Vice President | Geoffrey M. Nichol |
| Price Open | $72.51 |
| Previous Close | $76.50 |
| 52 Week Range | $71.53 - 106.74 |
| Market Capitalization | $13.7 B |
| Shares Outstanding | 179.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/24/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.51 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.5 B |
| Net Profit Margin | -7.24% |
| Return on Equity | -3.74% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
